<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20260502069236N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2026-05-17</date_registration>
      <primary_sponsor>Shahid Beheshti University of Medical Sciences</primary_sponsor>
      <public_title>Comparison of the effectiveness of two laser treatment methods for hand rejuvenation</public_title>
      <acronym></acronym>
      <scientific_title>Evaluation of the Effectiveness of Fractional CO₂ Laser Alone Versus Combined Fractional CO₂ Laser and Q-Switched Long-Pulsed 1064 nm Laser in Hand Rejuvenation</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2026-05-26</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>70</target_size>
      <recruitment_status>Recruiting</recruitment_status>
      <url>https://irct.ir/trial/89792</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: N/A, Blinding: Single blinded, Placebo: Not used, Assignment: Single, Purpose: Treatment, Blinding description: Several dermatologists, blinded to the type of laser used on each hand (CO₂ alone versus CO₂ combined with Q-switched laser), will offer their assessments concerning the comparison of the two hands.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Hand Rejuvenation.</hc_freetext>
      <i_freetext>Intervention 1: Intervention groIn this group, the hand allocated to the combination treatment will receive both Fractional Carbon Dioxide laser and Q-Switched Long-Pulsed Neodymium-Doped Yttrium Aluminum Garnet 1064 nm laser therapy.In each treatment session, Fractional Carbon Dioxide laser therapy will first be applied to the hand skin, followed by Q-Switched Long-Pulsed Neodymium-Doped Yttrium Aluminum Garnet laser treatment on the same area.Treatment will be performed in three sessions with intervals of 4 to 6 weeks between sessions. Prior to treatment initiation, standardized digital photography and skin analysis using the FotoFinder imaging system will be performed.Patients will be evaluated one month and three months after the final treatment session regarding the degree of hand skin rejuvenation, pigmentation changes, skin texture improvement, wrinkle reduction, and possible adverse effects. Intervention 2: Control group: In this group, the hand allocated to the control group will receive treatment with Fractional Carbon Dioxide laser alone.Treatment will be performed in three sessions with intervals of 4 to 6 weeks between sessions. Standardized digital photography and skin analysis using the FotoFinder imaging system will be conducted before treatment initiation.Patients will be followed one month and three months after the final treatment session, and clinical improvement, skin texture and pigmentation changes, and possible adverse effects will be evaluated and recorded.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is There is no further information</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Hasan Sharifian dorcheh</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Tehran - Shariati Street - Shahrdari Street - Minoo Dead End - Skin Research Center</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1989934148</zip>
        <telephone>+98 21 2274 1507</telephone>
        <email>Hasansh1150@gmail.com</email>
        <affiliation>Shahid Beheshti University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Hasan Sharifian dorcheh</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Tehran - Shariati St. - Shahrdari St. - Minoo Blvd. - Skin Research Center</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1989934148</zip>
        <telephone>+98 21 2274 1507</telephone>
        <email>Hasansh1150@gmail.com</email>
        <affiliation>Shahid Beheshti University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>They should have good overall health
Participation should be voluntary
They should have no prior history of skin disease</inclusion_criteria>
      <agemin>45 years</agemin>
      <agemax>55 years</agemax>
      <gender>Female</gender>
      <exclusion_criteria>active skin diseases on the hands such as eczema, psoriasis, skin infections, or open wounds
a history of abnormal scarring, including hypertrophic scars or keloids
use of photosensitizing medications
pregnancy or breastfeeding
psychiatric disorders or inability to adhere to treatment protocols and follow-up
a history of laser treatments or similar procedures on the hands within the past six months
systemic or autoimmune diseases such as lupus or scleroderma that may interfere with skin healing
severe allergies to light or materials used in the treatment</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code></hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword></hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Other</i_code>
      <i_code>Placebo</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention groIn this group, the hand allocated to the combination treatment will receive both Fractional Carbon Dioxide laser and Q-Switched Long-Pulsed Neodymium-Doped Yttrium Aluminum Garnet 1064 nm laser therapy.In each treatment session, Fractional Carbon Dioxide laser therapy will first be applied to the hand skin, followed by Q-Switched Long-Pulsed Neodymium-Doped Yttrium Aluminum Garnet laser treatment on the same area.Treatment will be performed in three sessions with intervals of 4 to 6 weeks between sessions. Prior to treatment initiation, standardized digital photography and skin analysis using the FotoFinder imaging system will be performed.Patients will be evaluated one month and three months after the final treatment session regarding the degree of hand skin rejuvenation, pigmentation changes, skin texture improvement, wrinkle reduction, and possible adverse effects.</i_keyword>
      <i_keyword>Control group: In this group, the hand allocated to the control group will receive treatment with Fractional Carbon Dioxide laser alone.Treatment will be performed in three sessions with intervals of 4 to 6 weeks between sessions. Standardized digital photography and skin analysis using the FotoFinder imaging system will be conducted before treatment initiation.Patients will be followed one month and three months after the final treatment session, and clinical improvement, skin texture and pigmentation changes, and possible adverse effects will be evaluated and recorded.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Change in the clinical improvement score of hand skin wrinkles based on dermatologist assessment using a four-grade clinical improvement scale. Timepoint: Before treatment, after each treatment session, and at one month and three months following the final treatment session. Method of measurement: This variable will be assessed using both objective and subjective methods. In the objective method, standardized digital photography of both hands will be performed under fixed conditions (constant lighting, angle, distance, and uniform background). Pre- and post-treatment images will be evaluated by two independent dermatologists blinded to the treatment allocation, and the degree of improvement will be reported as a percentage ranging from 0 to 100%. Treatment response will be classified as follows: low response (0–25% improvement), mild response (25–50% improvement), moderate response (50–75% improvement), and excellent response (greater than 75% improvement). In case of disagreement greater than one grade, a third dermatologist will be consulted. In the subjective method, patient satisfaction with treatment outcomes will be recorded through a standardized direct questionnaire. In addition, adverse events including edema, pain, erythema, pruritus, blistering, hypopigmentation, hyperpigmentation, and scarring will be assessed and documented by the treating physician at each visit.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Shahid Beheshti University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2026-01-07</approval_date>
        <contact_name>Ethics Committee of the Skin Research Center of Shahid Beheshti University of Medical Sciences</contact_name>
        <contact_address>Tehran, Qods Square, Shahrdari Street, not far from Tajrish Square, Tajrish Martyrs Medical Center, Skin Research Center Tehran Tehran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
